Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 28
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
CVS Health Corp
CVS
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$91.13
-1.40
-1.51%
Ult. Agg.: Oct 28, 5:47 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Dividendo:
La data di stacco del dividendo è stata 6 giorni fa
Utili:
I risultati di Q3 2026 tra 7 giorni da adesso in mer nov 4th, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 7 giorni alle 8:00 AM
Clicca per vedere il webcast
CVS Health Financials
CVS Health (CVS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
QUICK SPARK: UnitedHealth Calls 2026 the Bottom for Medicaid Margins
UnitedHealth expects Medicaid margins to bottom in 2026 and improve through 2028, UnitedHealthcare CEO Tim Noel says on earnings call.
Erica Kollmann
Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion
Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.
Vandana Singh
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.
Vandana Singh
PRO
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est
Benzinga Newsdesk
PRO
CVS Health Raises FY2026 GAAP EPS Guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 Est
CVS Health (NYSE:CVS) raises FY2026 GAAP EPS guidance from $6.24-$6.44 to $6.84-$7.04 vs $6.12 analyst estimate..
Benzinga Newsdesk
PRO
CVS Health Q2 Adj. EPS $2.58 Beats $1.85 Estimate, Sales $106.096B Beat $100.114B Estimate
=
Benzinga Newsdesk
